1. Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer
- Author
-
Giulia Petrone, Charles Gaulin, Andriy Derkach, Ashwin Kishtagari, Mark E. Robson, Rekha Parameswaran, and Eytan M. Stein
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
We aim to identify predictors of therapy-related myeloid neoplasms (t-MN) in patients with breast cancer (BC) and cytopenias to determine the timing of bone marrow biopsy (BMBx). Patients with BC and cytopenias who were referred for BMBx between 2002-2018 were identified using the Memorial Sloan Kettering Cancer Center institutional database. Characteristics associated with the risk of t-MN were evaluated by multivariable logistic regression and included in a predictive model. The average area under the receiver operating characteristic curve (AUC) was estimated by 5-fold cross-validation. Of the 206 BC patients who underwent BMBx included in our study, 107 had t-MN. By multivariable analysis, white blood cell count 4-11 K/mcL, absolute neutrophil count (ANC) ≥1.5 K/mcL, hemoglobin ≥12.2 g/dL, red cell distribution width 11.5-14.5%, the presence of bone metastasis and a time from BC diagnosis to BMBx
- Published
- 2022
- Full Text
- View/download PDF